All In Biotech

Drug Trial Radar · NCT01635647

A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso

A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children

Last checked: Nov 19, 2026Latest source record: Feb 15, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 730 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

730

Actual

Start

Nov 2012

Primary completion

Aug 2014

Study completion Sep 2014

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Jul 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Prevention
Who can join
All sexes, from 5 months, up to 17 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Prime boost vaccination with ChAd63 ME-TRAP followed eight weeks later with MVA ME-TRAP shows efficacy against malaria infection when tested in UK volunteers using sporozoite challenge experiments. It is a leading candidate vaccination strategy against malaria. In the field, Phase I studies have been conducted in adults in Kenya and The Gambia and children and infants in The Gambia. The vaccination strategy appears safe and well tolerated in these populations, and also shows impressive immunogenicity, not significantly different to that seen in the UK trials where efficacy was shown. In particular, recent data from The Gambia shows excellent safety and immunogenicity in infants in malaria endemic areas, who would be the ones to benefit most from such a vaccine against malaria. With this clinical development as background, the investigators now propose to evaluate efficacy against natural malaria infection in this important target group for an effective malaria vaccine, that is, 5-17 month infants and children living in malaria endemic areas. The proposed study area, Banfora, Burkina Faso, is highly endemic for Plasmodium falciparum malaria.

Conditions

  • Malaria

Interventions

  • ChAd63 ME-TRAP and MVA ME-TRAPBiological

    ChAd63 ME-TRAP: 5 x 10\^10vp MVA ME-TRAP: 1 x 10\^8 pfu heterologous prime-boost immunisation

  • Rabies vaccineBiological

    Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to first episode of malaria meeting the primary case definition of clinical malaria episodeTime frame: 6 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Clinical Vaccinology and 1. Centre National de Recherche et de Formation sur le Paludisme (CNRFP)/ Unité de Recherche Clinique de Banfora (URC-B)

    Ouagadougou, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.